^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF V600 mutation as an acquired resistance mechanism

Published date:
07/20/2021
Excerpt:
...a patient with EGFR mutated lung adenocarcinoma developing a BRAF V600 mutation as an acquired resistance mechanism...We present the case of a patient developing a BRAFV600 mutation as acquired resistance mechanism to osimertinib, who responded favorably to the combination of dabrafenib, trametinib and osimertinib.
DOI:
10.1016/j.lungcan.2021.06.025